Register

Interstitial lung disease   

Questions discussed in this category

When do you begin antifibrotic therapy for a patient with newly diagnosed ILD that is not IPF?
Do you base the decision on FEV1, 6MWD or symptoms at initial evaluation, or progression over time?
4 Answers available
What is the risk of ILD recurrence in MDA5/Ro52 positive dermatomyositis following a lung transplantation?
1 Answer available
How do you clinically distinguish between group I and group III PH in patients with CTD-ILD?
1 Answer available
Do you consider the use of antifibrotics at presentation in patients with a radiographic UIP pattern of pulmonary fibrosis in the presence of positive serologies without any symptoms of CTD (ie, fulfilling a possible diagnosis of IPAF) who have not yet demonstrated evidence of a progressive phenotype?
1 Answer available
What is your approach to treatment for a patient with progressive ILD (UIP pattern) with high titer RF but no articular symptoms?
1 Answer available
What indicators do you use to identify patients with CTD-ILD who do not have potential to improve from continued immunosuppressive therapy?
Do you use imaging (fibrosis vs. pneumonitis), PFTs, duration of prior immunosuppressive therapy?
1 Answer available
How do you approach the management of SSc-ILD in a patient on immune checkpoint therapy?
1 Answer available
Are there any concerns about using nintedanib in a patient with progressive fibrosing ILD on background mycophenolate?
1 Answer available
What is your initial treatment of choice in patients with RA and associated interstitial lung disease?
1 Answer available
How do you treat CTD-associated organizing pneumonia?
How is your approach to treatment different than other ILD patterns such as NSIP? Does treatment response vary based on underlying CTD?
2 Answers available
What is your approach to treatment for MDA5 dermatomyositis patients with rapidly progressive ILD?
Cyclophosphamide/tacrolimus and Rituximab have been used in conjunction with steroids in case series.
1 Answer available
How do you screen rheumatoid arthritis patients for lung disease (modality, frequency, patient selection)?
1 Answer available
Should methotrexate be categorically avoided in RA patients with COPD or RA-ILD?
1 Answer available
What is the role of nintedanib in the treatment of SSc-ILD?
The SENSCIS trial was published in 2019 on efficacy of this agent. However, it's not clear where this should be in the treatment algorithm: Monot...
2 Answers available
When do you use tacrolimus in patients with myositis-related interstitial lung disease?
1 Answer available
What agent do you try next in patients with myositis-related interstitial lung disease who are refractory to mycophenolate mofetil and azathioprine?
1 Answer available


Papers discussed in this category

N. Engl. J. Med., 2019 May 20
Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease.
The Lancet. Respiratory medicine, 2016-09
Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial.
The New England journal of medicine, 2006-06-22
Cyclophosphamide versus placebo in scleroderma lung disease.
Archives of internal medicine, 2008-09-22
Methotrexate is not associated with progression of interstitial lung disease in rheumatoid arthritis.
Arthritis and rheumatism, 2010-06
Incidence and mortality of interstitial lung disease in rheumatoid arthritis: a population-based study.
N Engl J Med,
Tofacitinib in Amyopathic Dermatomyositis-Associated Interstitial Lung Disease.
Nature reviews. Rheumatology, 2018-05
Treatment in myositis.
Lancet Respir Med, 2020 Aug 28
Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial.
Trials, 2017 Jun 15
Rituximab versus cyclophosphamide for the treatment of connective tissue disease-associated interstitial lung disease (RECITAL): study protocol for a randomised controlled trial.
N Engl J Med, 2019 Sep 29
Nintedanib in Progressive Fibrosing Interstitial Lung Diseases.
N Engl J Med, 2012 May 20
Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.
J Heart Lung Transplant, 2021 Nov
Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation.
Interact Cardiovasc Thorac Surg, 2015 Jan 07
Recurrent polymyositis-associated lung disease after lung transplantation.
Arthritis Rheum,
A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma.
The European respiratory journal, 2015-10
An official European Respiratory Society/American Thoracic Society research statement: interstitial pneumonia with autoimmune features.
The European respiratory journal, 2019-01
Risk stratification and medical therapy of pulmonary arterial hypertension.
Eur Respir J, 2019 Jan 24
Diagnosis of pulmonary hypertension.
Eur Respir J, 2019 Jan 24
Pulmonary hypertension in chronic lung disease and hypoxia.
Arthritis & rheumatology (Hoboken, N.J.), 2017-03
Progressive Decline of Lung Function in Rheumatoid Arthritis-Associated Interstitial Lung Disease.

Related Topics

Copyright © 2025 theMednet
All Rights Reserved.